Together with Novalyst Discovery and the group of Kristina Schoonjans from IGBMC, we applied our Fragment-based drug discovery approach to find and optimize molecules modulating the activity of a newly identified target for oncology.

This project called NOVALIX received a label from the globally-oriented competitiveness cluster “Innovations thérapeutiques”, coordinated by Alsace Biovalley.